The MYG1 Knockout Ca Ski Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the MYG1 gene in the Ca Ski human cervical carcinoma cell line. This loss-of-function model is generated through CRISPR/Cas9-mediated gene disruption, resulting in a heterogeneous pool of edited cells suitable for studying the biological consequences of MYG1 ablation. The polyclonal format offers researchers a robust, population-level tool to interrogate gene function without the constraints of a single clonal isolate, making it ideal for pathway analysis and phenotypic screening in cancer biology contexts.
Ca Ski cells are an adherent epithelial cell line originally derived from a cervical epidermoid carcinoma. These cells harbor integrated human papillomavirus type 16 (HPV-16) genomes and express viral oncoproteins E6 and E7, which contribute to their immortalized and tumorigenic properties. As a widely used model in cervical cancer research, Ca Ski cells recapitulate key features of HPV-driven carcinogenesis, including altered cell cycle regulation and apoptotic signaling. The availability of a MYG1 knockout in this genetic background enables dissection of mitochondrial functions within an HPV-positive epithelial environment.
MYG1 (Melanoma-Associated Antigen Family Member 1) encodes a mitochondrial exoribonuclease with 3′-5′ exonuclease activity that plays a critical role in mitochondrial RNA processing and decay. It acts downstream of proliferative signals and is transcriptionally regulated by the MITF transcription factor. MYG1 targets mitochondrial mRNAs, tRNAs, and rRNAs, thereby controlling the expression of oxidative phosphorylation complex components. It interacts with the mitochondrial RNA degradation machinery, including PNPT1, SUV3, and REXO2, and associates with mitochondrial ribosomal proteins. Disruption of MYG1 impairs mitochondrial RNA metabolism, potentially affecting energy production and cellular proliferation.
In the Ca Ski cervical cancer context, MYG1 knockout provides a physiologically relevant platform to investigate how mitochondrial RNA processing influences tumor cell behavior. Since MYG1 is implicated in cell proliferation and its expression has been associated with melanoma and other cancers, studying its loss in HPV-positive carcinoma cells may reveal vulnerabilities linked to mitochondrial gene expression. This model can help elucidate the interplay between mitochondrial function and HPV oncogenic signaling, contributing to a deeper understanding of cervical cancer pathobiology.
This polyclonal knockout product is suitable for a range of downstream analyses including mitochondrial RNA-seq, RT-qPCR, Western blotting, cell proliferation and apoptosis assays, metabolic profiling, and migration studies. It also enables drug sensitivity screening focused on mitochondrial targets, as well as functional genomics investigations of the exoribonuclease pathway involving PNPT1, SUV3, and REXO2. Researchers can employ this model to identify synthetic lethal interactions or to evaluate compounds that exploit mitochondrial vulnerabilities in cancer. For additional technical details, please contact Ascent Research.
